Akademik Veri Yönetim Sistemi
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, ss.279-282, 2023 (ESCI)
Aim: Extrapulmonary neuroendocrine carcinomas are rare tumors and clinical trials for their treatment are limited. In this study, we aimed to determine the impact of clinicopathological and prognostic factors on platinum response in patients diagnosed with advanced EP-NECs. Material and Methods: Patients diagnosed with extrapulmonary neuroendocrine carcinoma were included in the study. General characteristics and response rates were saved. Univariate and multivariate analyses were used to determine prognostic factors. We divided patients into three groups: pancreatic, gastrointestinal and other extrapulmonary primary. Progression-free survivals were compared to each other. Results: We analyzed 37 patients in our study. The median age was 60 in our study. The most frequent primary origin of neuroendocrine carcinoma was the pancreas. Liver metastases were correlated with poor progression-free survival. Overall response rate was achieved in 26 patients (70%). PFS was 6 months in all groups and 4 for gastrointestinal, 8 for pancreatic, 9 months for other extrapulmonary NECs (p=0.37). Discussion: Due to the rare incidence of the disease, few randomized controlled trials have been conducted. These treatment recommendations are extrapolated from small cell lung cancer trials. Most of the patients diagnosed with advanced extrapulmonary neuroendocrine carcinomas responded to platinum-based therapy. Liver metastasis was a poor prognostic factor for progression-free survival.